Literature DB >> 20494607

Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy.

Christine D Esper1, Alan Freeman, Stewart A Factor.   

Abstract

The purpose of this study was to examine lingual protrusion dystonia (LPD); its frequency, etiology and response to botulinum toxin therapy. Previous literature suggests that LPD is more frequently the result of heredodegenerative disease and that the use of botulinum toxin therapy in LPD is associated with significant adverse effects. This is a retrospective database and record review from a movement disorder clinic. Of 421 dystonia patients, we identified 17 with LPD (4%). Of these cases, the diagnoses were: primary cranial dystonia (5), primary generalized dystonia (2), tardive dystonia (7), heredodegenerative disease (1), multifactorial (1) and post-infectious (1). All primary cases had concomitant oromandibular dystonia. In some secondary cases the LPD was the only cranial feature. Nine received botulinum toxin injections and 55.6% sustained moderate or marked improvement. Of 89 total botulinum toxin sessions, 66.3% had an excellent response, and 92.1% had some response. 97.8% of the sessions resulted in no significant adverse effects. On one occasion one patient developed severe dysphagia requiring placement of a percutaneous gastrostomy (PEG) tube. We conclude that LPD is rare, most commonly the result of tardive and primary dystonia. Botulinum toxin therapy may be very effective but needs to be utilized with care because of the possibility for the development of dysphagia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494607     DOI: 10.1016/j.parkreldis.2010.04.007

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  23 in total

Review 1.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

2.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue.

Authors:  Laura Nastasi; Giovanni Mostile; Alessandra Nicoletti; Mario Zappia; Ester Reggio; Santiago Catania
Journal:  J Neurol       Date:  2016-06-08       Impact factor: 4.849

Review 4.  Diagnosis and treatment of dystonia.

Authors:  H A Jinnah; Stewart A Factor
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

5.  Dystonia in Patients With Spinocerebellar Ataxia Type 2.

Authors:  Vladana Markovic; Natasa T Dragasevic-Miskovic; Iva Stankovic; Igor Petrovic; Marina Svetel; Vladimir S Kostić
Journal:  Mov Disord Clin Pract       Date:  2015-12-14

Review 6.  Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.

Authors:  Katharina Stegmayer; Sebastian Walther; Peter van Harten
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

7.  Tardive dyskinesia.

Authors:  Pratibha G Aia; Gonzalo J Revuelta; Leslie J Cloud; Stewart A Factor
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

8.  Pilot Single-Blind Trial of AbobotulinumtoxinA in Oromandibular Dystonia.

Authors:  Laura M Scorr; Michael R Silver; John Hanfelt; Elaine Sperin; Alan Freeman; H A Jinnah; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 9.  The focal dystonias: current views and challenges for future research.

Authors:  H A Jinnah; Alfredo Berardelli; Cynthia Comella; Giovanni Defazio; Mahlon R Delong; Stewart Factor; Wendy R Galpern; Mark Hallett; Christy L Ludlow; Joel S Perlmutter; Ami R Rosen
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

Review 10.  Botulinum Toxin Treatment of Movement Disorders.

Authors:  Yasaman Safarpour; Bahman Jabbari
Journal:  Curr Treat Options Neurol       Date:  2018-02-24       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.